Non–Invasive Prenatal Testing(NIPT) Market 2021 Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Forecast by 2025


News provided by

Shibuya Data Count

Jan 05, 2022, 01:24 EST


Shibuya-ku, Tokyo, Japan, Japan, Jan 05, 2022, 01:24 /Comserve / -- China Potential Non–Invasive Prenatal Testing (NIPT) market is likely to reach more than US$ 1.7 Billion by 2024.

China Potential Non–Invasive Prenatal Testing (NIPT) market is likely to reach more than US$ 1.7 Billion by 2024.

Long–term Growth Projection and Development:

• It is predicted that China Actual NIPT test volume will increase to 1.6 Million by 2024
• More than 3,00,000 NIFTY tests done in 2016
• Berry Genomics completes US$ 648 Million reverse merger in Shenzhen
• Two–Child policy is likely to boost China NIPT market

Get A Sample Copy Of This Report With Graphs And Charts:-  https://www.sdki.jp/sample-request-53468

Growth in China NIPT market can be attributed to factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). High test cost, strict regulatory requirements and ethical hurdles is restraining the growth of China NIPT market. Due to expanding patient access to NIPT test, the China NIPT test market is poised to have a positive outlook in the year ahead.

The research report titled “Non–Invasive Prenatal Testing(NIPT) Market Outlook 2024: China Opportunity and Demand Analysis, Market Forecast 2017–2024” examines the market dynamics, competitive landscape and discusses major trends. The study describes an in–depth analysis of the China actual and potential NIPT market.

The report contains a granular analysis of the market segmentation, reveal facts on the market size, volume and revenues; and provides forecasts through 2024. It also includes a snapshot of the NIPT implementation in the low and middle-income countries. The report also explores detailed description of growth drivers and inhibitors of the China NIPT Market.

The report concludes with the profiles of major players in the China NIPT Market. The key market players are evaluated on various parameters such as company introduction, NIPT test portfolio, NIPT test analysis with volume and market revenue and latest development/updates of the NIPT Market in China.

Key Topics Covered in the Report

• 2013 - 2024: China Potential NIPT Test Market Size & Analysis (Volume and Value)
• 2013 - 2024: China Actual NIPT Test Market Size & Analysis (Volume and Value)
• NIPT Test Implementation in Low & Middle–Income Countries
• Key Companies Analysis
• Key Drivers and Inhibitors of the China NIPT Test Market

Get A Sample Copy Of This Report With Graphs And Charts:-  https://www.sdki.jp/sample-request-53468

Key Companies Covered in the Report are as follows:

• Berry Genomics
• BGI Diagnosis Co., Ltd
• Basetra

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.


For more information, please contact:

Lauren Brown

Shibuya Data Count
Email: sales@sdki.jp
Tel: + 81 50 50509159

Related Links
https://www.sdki.us/



Also from this source


Micro Mobile Data Center Market Size, Share 2021 Global Industry Trends, Growth Drivers, Demands, Business Opportunities and Demand Forecast to 2025

The report offers overview of leading companies encompassing their successful marketing strategies,


Chromatography Reagents Market Size Is Projected To Reach USD 5.5 Billion In 2020, At A CAGR Of 7.1% During Forecast Period

Increasing R&D investments in the pharmaceutical and biotechnology industry is creating demand oppor